Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdiction ...

Financial Data and Key Metrics Changes - The company completed the sale of its subsidiary, Trans Ova Genetics, for $170 million, which allowed for the retirement of $144 million in convertible notes, reducing outstanding debt to $56 million [29][30][34] - SG&A expenses decreased by 8% quarter-over-quarter and 9% year-to-date compared to the previous year, enabling a focus on clinical advancement and potential commercialization [32][33] - The company ended Q3 2022 with cash, cash equivalents, short-term investments, and restricted cash totaling $153.8 million, providing a cash runway into early Q4 2023 [35] Business Line Data and Key Metrics Changes - The AdenoVerse immunotherapy platform, particularly PRGN-2012 for Recurrent Respiratory Papillomatosis (RRP), is progressing rapidly with 15 patients treated and a strong safety profile reported [10][13] - PRGN-2009 for HPV-associated cancers has shown a 40% objective response rate in interim data from the Phase I combination arm [19][21] - Enrollment for PRGN-3006 in the UltraCAR-T trial for relapsed refractory AML is complete, with upcoming presentations expected to showcase safety and efficacy data [22][24] Market Data and Key Metrics Changes - The estimated market opportunity for PRGN-2012 in RRP is projected to exceed $1 billion in the U.S. and EU alone, with a global patient population potentially over 75,000 [15][16] - The company is focusing on markets with high unmet needs, aiming for accelerated regulatory pathways for its therapies [6][7] Company Strategy and Development Direction - The company emphasizes fiscal discipline and has reduced SG&A costs to allocate more resources towards clinical and commercialization efforts [9][34] - The strategy includes advancing differentiated therapies with potential for unique pricing models, leveraging the UltraPorator technology for decentralized manufacturing [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data presentations and the potential for significant advancements in their clinical pipeline [78][79] - The company is focused on creating shareholder value and addressing high unmet medical needs through innovative treatments [80] Other Important Information - The company is actively engaging with the FDA regarding regulatory pathways for its therapies, particularly for PRGN-2012 [60][68] - The UltraCAR-T platform is positioned as a unique solution for solid tumors, with ongoing discussions about its potential in the market [27][42] Q&A Session Summary Question: Can you provide details on the patients enrolled in the Phase II trial for PRGN-2012? - Management indicated that the patients treated have severe cases, often requiring multiple surgeries, highlighting the challenging nature of the disease [38] Question: What can you share about the patient who was retreated in the PRGN-3005 trial? - The patient is reportedly doing well after receiving a repeat dose, with positive expectations for future reports [40][41] Question: What factors influenced the decision to focus on dose Level 3 for the AML UltraCAR-T program? - The decision was based on previously reported efficacy and safety data, with a focus on expanding patient recruitment [45][47] Question: What is the status of the ROR1 3007 UltraCAR-T program? - Management noted that internal processes and committee approvals are the current gating factors for initiating patient dosing [52] Question: How is the repeat dosing regimen determined for patients in the UltraCAR-T programs? - The dosing is personalized based on the oncologist's discretion, differing from conventional therapies that require fixed schedules [61][63]

Financial Performance - Total revenues for the three months ended September 30, 2022, were $16,722,000, a significant increase from $3,333,000 in the same period of 2021, representing a growth of 402%[24] - The company reported a net income of $87,379,000 for the three months ended September 30, 2022, compared to a net loss of $29,764,000 in the same period of 2021[27] - For the nine months ended September 30, 2022, the company reported a net income of $50,493, compared to a net loss of $67,132 for the same period in 2021[36] - The company reported a comprehensive income of $84,754,000 for the three months ended September 30, 2022, compared to a comprehensive loss of $30,790,000 in the same period of 2021[27] - Total consolidated revenues for the nine months ended September 30, 2022, were $25,146 million, a significant increase from $10,583 million in the same period of 2021, representing a growth of approximately 138.5%[157] - Operating loss decreased to $7.6 million for the three months ended September 30, 2022, from a loss of $21.5 million in the same period in 2021, reflecting an improvement of $13.9 million, or 64.6%[215] - Loss from continuing operations decreased to $7.6 million for the three months ended September 30, 2022, compared to a loss of $26.3 million in the same period in 2021, an improvement of $18.7 million, or 71.0%[215] Assets and Liabilities - Total current assets increased to $162,806,000 as of September 30, 2022, compared to $156,628,000 as of December 31, 2021[18] - The company's total liabilities decreased to $116,713,000 as of September 30, 2022, from $252,508,000 as of December 31, 2021, indicating a reduction of approximately 54%[21] - The company’s total assets were $259,245,000 as of September 30, 2022, down from $359,856,000 as of December 31, 2021[18] - The accumulated deficit as of September 30, 2022, was $1,846,391,000, a decrease from $1,915,556,000 as of December 31, 2021[21] - Long-term debt decreased to $82,069 as of September 30, 2022, from $179,934 as of December 31, 2021, reflecting a reduction of approximately 54.4%[105] Cash Flow and Investments - Cash and cash equivalents decreased to $9,067,000 as of September 30, 2022, down from $36,423,000 as of December 31, 2021[18] - Cash used in operating activities for the nine months ended September 30, 2022, was $49,649, compared to $41,182 for the same period in 2021[36] - The company generated $214,996 in net cash from investing activities for the nine months ended September 30, 2022, compared to a net cash used of $90,469 in 2021[39] - The company had $153,770 in cash, cash equivalents, short-term investments, and restricted cash as of September 30, 2022[48] Research and Development - Research and development expenses for the nine months ended September 30, 2022, were $36,377,000, slightly up from $35,755,000 in the same period of 2021[24] - Research and development expenses for the Biopharmaceuticals segment were $12.536 million for Q3 2022, compared to $12.355 million in Q3 2021, reflecting ongoing investment in proprietary programs[205] - Total consolidated research and development expenses for the nine months ended September 30, 2022, were $36.377 million, slightly up from $35.755 million in the same period of 2021[205] Operational Changes and Future Outlook - The company expects to continue incurring operating losses and negative cash flows from operations for the foreseeable future, requiring additional capital to fund its operations[48] - As of September 30, 2022, the company had no committed source of additional funding from either debt or equity financings[48] - The company has shifted focus to healthcare, resulting in the termination of several collaboration agreements and a decrease in collaboration revenues expected in the near term[200] - The company anticipates continued significant losses in the foreseeable future, with no assurance of achieving profitability[195] Segment Performance - Revenues from external customers in the Biopharmaceuticals segment for the three months ended September 30, 2022, were $14,624 million, a significant increase from $129 million in the same period of 2021[154] - The total segment revenues for the Exemplar segment for the three months ended September 30, 2022, were $2,098 million, compared to $3,204 million in the same period of 2021[154] - Precigen's Exemplar segment generated positive Segment Adjusted EBITDA in the nine months ended September 30, 2022, indicating operational profitability[195] Divestitures and Acquisitions - The company completed the sale of its subsidiary Trans Ova Genetics on August 18, 2022, which was previously a separate reportable segment[45] - The Company completed the sale of its subsidiary Trans Ova for $170 million, with an additional potential earn-out of up to $10 million based on performance in 2022 and 2023[65] - The Company recognized a gain on the divestiture of Trans Ova amounting to $94.7 million for the nine months ended September 30, 2022[69] COVID-19 Impact - The Company is closely monitoring the impact of COVID-19, which has caused uncertainty regarding its clinical and preclinical pipeline candidates[52] - The impact of COVID-19 on the company's operations remains uncertain, with potential delays in clinical and preclinical pipeline candidates[184] Stock and Financing - The company entered into a Controlled Equity Offering Sales Agreement to issue and sell up to $100,000 of its common stock, with no shares sold during the three months ended September 30, 2022[125][126] - The company has convertible notes with a face value of $82,440 due on July 1, 2023, raising substantial doubt about its ability to continue as a going concern[48] - The company successfully retired $117,560 of principal balance from the convertible notes during the three months ended September 30, 2022, recording a gain on extinguishment of debt of approximately $853[113] Other Financial Metrics - The effective interest rate on the convertible notes was 4.25% as of September 30, 2022[115] - The total interest expense for the nine months ended September 30, 2022, was $6,131 million, down from $13,891 million in the same period of 2021, indicating a significant reduction[116] - The company had U.S. taxable income of approximately $44,300 for the three months ended September 30, 2022, compared to a taxable loss of approximately $24,700 for the same period in 2021[118]

Precigen, Inc. (NASDAQ:PGEN) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen Sabzevari - President and Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Nick Abbott - Wells Fargo Securities, LLC Jason Butler - JMP Securities, LLC Jennifer Kim - Cantor Fitzgerald & Co. Operator Good day, and welcome to the Precigen Second Quarter and First Half 2022 Financial Resul ...

| --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|-------------------------------------------------| | | | | | | | Precigen, Inc. | | | | | | | | | | | | | | | | Q2 and 1H '22 Earnings and Business Update Call | Forward-looking Statements 2 Some of the statements made in this presenta0on are forward-looking statements. These forward-looking statements are based upon the Company's current expecta0ons and projec0ons about future events and generally relate to plans, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdiction of incorporation or organization) 20374 Seneca Meadows Parkway Germantown, Maryland 20876 (Address of principal executive offices) (Z ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other jurisdiction ...

© Precigen. All rights reserved. Precigen, Inc. January 12, 2022 Helen Sabzevari, PhD President & Chief Executive Officer 40th Annual J.P. Morgan Healthcare Conference Forward-looking Statements 2 Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Precigen's current expectations and projections about future events and generally rela ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in its charter) Virginia 26-0084895 (State or other ju ...